🇺🇸 Placlitaxel in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 10
Most-reported reactions
- Atrial Fibrillation — 1 report (10%)
- Axonal Neuropathy — 1 report (10%)
- Bacteraemia — 1 report (10%)
- Blood Immunoglobulin E Increased — 1 report (10%)
- Chest Pain — 1 report (10%)
- Decreased Appetite — 1 report (10%)
- Demyelinating Polyneuropathy — 1 report (10%)
- Drug Effect Decreased — 1 report (10%)
- Drug Interaction — 1 report (10%)
- Dyspnoea — 1 report (10%)
Other Other approved in United States
Frequently asked questions
Is Placlitaxel approved in United States?
Placlitaxel does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Placlitaxel in United States?
Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.